PDMR Shareholding/Share Incentive Plan & TVRs
Diaceutics PLC has announced that on July 31, 2026, trustees purchased ordinary shares for three Persons Discharging Managerial Responsibilities (PDMRs) under the company's Share Incentive Plan, with the company matching these purchases on a 1:1 basis. Specifically, 5,359 shares were issued to the UK Trust for UK SIP participants. In addition to these matched awards, 64,083 shares were allotted during July 2026 to settle employee share option exercises. Consequently, the total number of Diaceutics shares in issue is now 85,149,159, which shareholders should use for disclosure calculations.
Select text to share a quote on X · sign in to keep highlights & notes in your DXRX notes
New York, Belfast and London, 4 August 2026 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, has been notified that on 31 July 2026, Global Shares Trustees (UK) Limited (the "UK Trust") and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares of £0.002 in the capital of the Company ("Shares") on behalf of Susanne Munksted, Jordan Clark and Nick Roberts (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employees. These purchases will be made each month until further notice.
As announced on 2 October 2023, application was made to AIM for a block listing of 1,500,000 Shares to facilitate the admission of the Shares to trading following the exercise of options inter alia under the SIP Schemes. The matched share awards for the UK PDMRs, along with those for all other participants in the UK SIP Scheme, have been settled by the Company issuing 5,359 Shares on 3 August 2026 to the UK Trust. The Trust will hold these Shares on behalf of participants until they vest in accordance with the UK Scheme rules.
During the period from the last Total Voting Rights Announcement on 3 July 2026, 64,083 Shares were allotted to settle certain employee share option exercises during July 2026 in addition to the Shares allotted as a result of the Share Incentive Plan transactions announced today. As a result, the number of Shares Diaceutics has in issue is 85,149,159. This figure may be used by shareholders in the Company as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
| a. | Name | Susanne Munksted |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Precision Medicine Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £ 0.002 each ISIN: GB00BJQTGV64 |
| c. | Price(s) and volume(s) | Share purchase: |
| Price(s) | Volume(s) | |
| 144.0 p | 102 | |
| Conditional share award: | ||
| Price(s) | Volume(s) | |
| Nil | 102 | |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Jordan Clark |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Data Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £ 0.002 each ISIN: GB00BJQTGV64 |
| c. | Price(s) and volume(s) | Share purchase: |
| Price(s) | Volume(s) | |
| 144.0 p | 104 | |
| Matched share award: | ||
| Price(s) | Volume(s) | |
| Nil | 104 | |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Nick Roberts |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Finance Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £ 0.002 each ISIN: GB00BJQTGV64 |
| c. | Price(s) and volume(s) | Share purchase: |
| Price(s) | Volume(s) | |
| 144.0 p | 104 | |
| Matched share award: | ||
| Price(s) | Volume(s) | |
| Nil | 104 | |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.